Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 1Aggression 1

Interventions

pembrolizumab 7Cyclophosphamide 5Metformin 4durvalumab 3Vincristine 3Radiation 3Imiquimod 3Fluorouracil 3antitumor A 2Testosterone 2Surveys and Questionnaires 2Rituximab 2Prednisone 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Lapatinib 2Immunoglobulin G 2HhAntag691 2Doxorubicin 2Disulfides 2Cisplatin 2Biopsy 2xentuzumab 1tremelimumab 1ribociclib 1posaconazole 1pexidartinib 1perflutren 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Has results × Bexarotene × Clear all
NCT00718770 2014-01-17

A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression

University of Colorado, Denver

Phase EARLY_PHASE1 Completed
10 enrolled 5 charts
Head & Neck

Aggression, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡